Skip to content
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Pulmonology · Pulmonary Mycobacterium avium complex disease

When Is Watchful Waiting Appropriate for Pulmonary MAC?

At a Glance

Watchful waiting may suit selected people with mild pulmonary MAC without lung cavities, low bacterial levels, stable symptoms and lung function, and a healthy immune system. It is active monitoring—not doing nothing—and antibiotics may be needed if disease or symptoms worsen.

Watchful waiting—also known as active observation—may be considered for selected patients with mild, noncavitary pulmonary Mycobacterium avium complex (MAC) disease [1][2]. Because untreated MAC can progress and cause irreversible lung damage, treatment is generally discussed for all patients who meet the formal diagnostic criteria (which requires compatible symptoms, chest imaging, and repeated positive sputum cultures or a bronchoscopy sample) [3][4]. However, some patients and their NTM-experienced doctors choose observation as an individualized alternative [2][5]. This decision balances the risk of lung damage against the long, complex, and potentially toxic course of antibiotics required to treat MAC [6].

Watchful waiting is never simply “wait and see.” It is an active, monitored strategy that involves scheduled testing, airway clearance, and ongoing symptom review [4][7].

What Does Active Observation Involve?

If you and your care team choose to observe the disease rather than start antibiotics immediately, your plan will be individualized but typically includes:

  • Airway clearance: An airway-clearance plan, often performed regularly if recommended by your clinician, may help move mucus and manage the underlying bronchiectasis (widened, damaged airways) [8][9]. Note: Airway clearance does not eradicate MAC or guarantee the disease will not progress, but it is standard care for managing mucus.
  • Individualized monitoring: Your team will establish a schedule for chest CT scans or X-rays, pulmonary function tests (like FEV1, which measures how much air you can forcefully exhale in one second), and sputum cultures. The frequency is tailored to minimize radiation while safely tracking the disease [4][7].
  • Nutritional and health support: Tracking your weight and Body Mass Index (BMI) is important, as low weight or poor nutrition are risk factors for MAC progression [9][10].
  • Symptom tracking: Monitoring changes in cough, fatigue, fever, night sweats, or unexplained weight loss [8].

In some untreated patients with stable MAC, sputum cultures may spontaneously become negative without antibiotics (seen in about 34% to 52% of mild cases in observational studies) [4][11]. However, this is unpredictable, does not cure the underlying bronchiectasis, and the infection can return [4]. Long-term periodic monitoring remains necessary.

Weighing the Options: Observation vs. Treatment

The choice between observation and antibiotics is a shared decision based on your clinical picture, disease severity, and personal preferences [10].

Factors that may favor Observation (Watchful Waiting):

  • Nodular-bronchiectatic pattern: Imaging shows small nodules and widened airways without cavities. This form tends to progress more slowly [1][12].
  • Low bacterial burden: Sputum smears (a rapid microscope test for acid-fast bacilli, or AFB) are negative [8][4].
  • Stable health: Symptoms are minimal, lung function is stable, and body weight is maintained [10][11].
  • Intact immune system: You are not taking immunosuppressants or biologics (powerful drugs that alter the immune system) [5][13].

Factors that strongly favor starting Antibiotic Treatment:

  • Cavitary disease: The CT scan shows holes (cavities) in the lung tissue. Cavitary MAC is associated with faster progression and higher risk of long-term lung damage, so treatment is generally indicated at diagnosis [2][12].
  • High bacterial burden: Sputum smears are positive, indicating a larger amount of bacteria [8][4].
  • Declining health metrics: Worsening lung function (FEV1), declining BMI, or significant systemic symptoms like fevers, night sweats, and weight loss [14][10].

Signs It Is Time to Reassess

If you are observing the disease, your clinician will watch for changes that suggest a transition to antibiotics is needed. Prompt reassessment is warranted if:

  • New cavities form or scans show the disease spreading to more lobes of the lungs (radiographic progression) [15][16].
  • Sputum cultures are persistently positive over multiple visits, especially if the AFB smear turns positive [17][10].
  • Symptoms worsen, even if your scan looks stable [8].

Important Safety Warning: If you begin coughing up blood (hemoptysis), or notice an increase in the amount of blood, contact your care team promptly. Seek emergency care for heavy bleeding, chest pain, dizziness, or breathing difficulty [18]. Do not intensify your airway clearance techniques during significant bleeding without clinician guidance.

Understanding the Burden of Antibiotics

When MAC treatment is started, it requires a complex regimen of multiple antibiotics. Crucially, the timeline is not just a standard 12 months; guidelines state treatment should usually continue for at least 12 months after your sputum cultures turn negative [2][19].

The medications can cause potentially serious side effects. A recent meta-analysis found that adverse drug reactions occurred in roughly 57% of patients treated for MAC, with about 15% needing to stop the drugs entirely [6]. Your specialist will regularly monitor your hearing, vision, liver function, and kidney health while you are on therapy to manage these risks. For some patients with mild disease, these immediate side effects and drug interactions outweigh the near-term benefits, making active observation a reasonable alternative [2][5].

Common questions in this guide

What does watchful waiting mean for pulmonary MAC disease?
Watchful waiting, also called active observation, means delaying antibiotics while actively monitoring the disease. A plan may include airway clearance, symptom reviews, sputum cultures, chest imaging, and lung-function tests, with treatment reconsidered if the disease progresses.
Which people with pulmonary MAC may be able to observe instead of starting antibiotics?
Observation may be considered for people with mild disease without cavities, small nodules and widened airways, negative sputum smears, stable symptoms and lung function, maintained weight, and no immune-suppressing treatment. The choice is individualized with an NTM-experienced clinician because MAC can still progress without treatment.
What changes mean I should reconsider antibiotics for MAC?
Antibiotics become more strongly favored if CT scans show cavities or disease spreading, sputum cultures stay positive, or an acid-fast smear becomes positive. Worsening symptoms, declining lung function, weight loss, fever, night sweats, or falling weight should also prompt a timely review with your clinician.
How is pulmonary MAC monitored during active observation?
Your clinician will set an individualized schedule for chest CT scans or X-rays, lung-function testing, and sputum cultures. The plan also includes tracking symptoms, weight, nutrition, and airway-clearance needs; there is no single schedule for everyone.
Can pulmonary MAC go away without antibiotics?
In some mild cases, sputum cultures become negative without antibiotics, but this is unpredictable and does not necessarily eliminate the infection or repair underlying bronchiectasis. MAC can return, so ongoing periodic monitoring is still needed.
What should I know about the risks of MAC antibiotic treatment?
Treatment usually combines several antibiotics and generally continues for at least 12 months after sputum cultures turn negative. The medicines can cause side effects and interactions, so clinicians may monitor hearing, vision, liver function, and kidney health.
When is coughing blood from MAC an emergency?
Contact your care team promptly if you cough up blood or the amount increases. Heavy bleeding, chest pain, dizziness, or breathing difficulty requires emergency care, and you should not intensify airway clearance during significant bleeding unless your clinician advises it.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my current disease meet the formal diagnostic criteria for MAC, and what is my estimated risk of progression if we observe?
  2. 2.Is my MAC strain macrolide-susceptible, and how does that affect my treatment options?
  3. 3.What specific symptoms or changes in my sputum, weight, or breathing would make you recommend starting antibiotics?
  4. 4.What is our individualized schedule for repeating CT scans, lung function tests, and sputum cultures?
  5. 5.What baseline tests (like eye exams, hearing tests, or liver panels) will I need before starting treatment, if we go that route?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Treatment of nontuberculous mycobacterial pulmonary disease requires a stepwise and multidisciplinary approach.

    Lemson A, van Laarhoven A, Kurver L, et al.

    Expert review of respiratory medicine 2025; (19(4)):287-299 doi:10.1080/17476348.2025.2479615.

    PMID: 40114560
  2. 2

    Treatment for Mycobacterium avium complex lung disease.

    Pan SW, Shu CC, Feng JY, Su WJ

    Journal of the Formosan Medical Association = Taiwan yi zhi 2020; (119 Suppl 1()):S67-S75 doi:10.1016/j.jfma.2020.05.006.

    PMID: 32446754
  3. 3

    Mycobacterium avium Complex: Addressing Gaps in Diagnosis and Management.

    Daley CL, Winthrop KL

    The Journal of infectious diseases 2020; (222(Suppl 4)):S199-S211 doi:10.1093/infdis/jiaa354.

    PMID: 32814943
  4. 4

    Long-term natural history of non-cavitary nodular bronchiectatic nontuberculous mycobacterial pulmonary disease.

    Moon SM, Jhun BW, Baek SY, et al.

    Respiratory medicine 2019; (151()):1-7 doi:10.1016/j.rmed.2019.03.014.

    PMID: 31047103
  5. 5

    Mycobacterium avium Complex Disease.

    Daley CL

    Microbiology spectrum 2017; (5(2)) doi:10.1128/microbiolspec.TNMI7-0045-2017.

    PMID: 28429679
  6. 6

    Adverse drug reactions during nontuberculous mycobacterial pulmonary disease treatment: a systematic review and meta-analysis.

    Kim J, Oh J, Kang YA, et al.

    Annals of the American Thoracic Society 2026; (23(2)):292-302 doi:10.1513/AnnalsATS.202412-1307OC.

    PMID: 40986804
  7. 7

    Beyond Symptoms: Radiologic identification of asymptomatic Mycobacterium avium complex pulmonary infections.

    Fujiwara K, Watanabe F, Uesugi F, et al.

    Respiratory medicine 2024; (226()):107627 doi:10.1016/j.rmed.2024.107627.

    PMID: 38604553
  8. 8

    Predictors of treatment initiation in nontuberculous mycobacterial pulmonary disease: a real-life retrospective analysis.

    Fumagalli G, Riccardi N, Nadalin M, et al.

    European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2026; doi:10.1007/s10096-026-05562-w.

    PMID: 42249218
  9. 9

    Managing Mycobacterium avium Complex Lung Disease With a Little Help From My Friend.

    Griffith DE, Aksamit TR

    Chest 2021; (159(4)):1372-1381 doi:10.1016/j.chest.2020.10.031.

    PMID: 33080299
  10. 10

    Retrospective evaluation of natural course in mild cases of Mycobacterium avium complex pulmonary disease.

    Kimizuka Y, Hoshino Y, Nishimura T, et al.

    PloS one 2019; (14(4)):e0216034 doi:10.1371/journal.pone.0216034.

    PMID: 31022253
  11. 11

    Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course.

    Hwang JA, Kim S, Jo KW, Shim TS

    The European respiratory journal 2017; (49(3)) doi:10.1183/13993003.00537-2016.

    PMID: 28275170
  12. 12

    Treatment of Mycobacterium avium Complex (MAC).

    Griffith DE

    Seminars in respiratory and critical care medicine 2018; (39(3)):351-361 doi:10.1055/s-0038-1660472.

    PMID: 30071550
  13. 13

    Risk stratification for the development of chronic pulmonary aspergillosis in patients with Mycobacterium avium complex lung disease.

    Furuuchi K, Ito A, Hashimoto T, et al.

    Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy 2018; (24(8)):654-659 doi:10.1016/j.jiac.2018.04.002.

    PMID: 29705392
  14. 14

    Rates and Risk Factors of Progression in Patients With Nontuberculous Mycobacterial Pulmonary Disease: Secondary Analysis of a Prospective Cohort Study.

    Hyung K, Kim SA, Kim JY, et al.

    Chest 2024; (166(3)):452-460 doi:10.1016/j.chest.2024.03.024.

    PMID: 38499238
  15. 15

    Predictors of radiological aggravations of pulmonary MAC disease.

    Kodaka N, Nakano C, Oshio T, et al.

    PloS one 2020; (15(8)):e0237071 doi:10.1371/journal.pone.0237071.

    PMID: 32760104
  16. 16

    Treatment of Mycobacterium avium Complex Pulmonary Disease.

    Kwon YS, Koh WJ, Daley CL

    Tuberculosis and respiratory diseases 2019; (82(1)):15-26 doi:10.4046/trd.2018.0060.

    PMID: 30574687
  17. 17

    Microbiological Persistence in Patients With Mycobacterium avium Complex Lung Disease: The Predictors and the Impact on Radiographic Progression.

    Pan SW, Shu CC, Feng JY, et al.

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2017; (65(6)):927-934 doi:10.1093/cid/cix479.

    PMID: 28541556
  18. 18

    MAC Attack: Clinical Correlates of Mycobacterium avium Complex Infection Among Patients With and Without Cancer.

    Gupta K, Feinstein MB, Goldman DA, et al.

    Journal of clinical medicine research 2020; (12(3)):142-149 doi:10.14740/jocmr4058.

    PMID: 32231749
  19. 19

    Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments.

    Kumar K, Daley CL, Griffith DE, Loebinger MR

    European respiratory review : an official journal of the European Respiratory Society 2022; (31(163)) doi:10.1183/16000617.0212-2021.

    PMID: 35140106

This page is for informational purposes only and does not constitute medical advice. Decisions about observing or treating pulmonary MAC disease should be made with your NTM-experienced clinician based on your test results and health.

Get notified when new evidence is published on Mycobacterium avium complex disease.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.